Equillium, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $88.1M
- Price
- $1.39
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.11%
- Volume
- 343.3K
About
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
Quick stats
Shares outstanding63.4M
Computed float44.8M
Float / shares70.6%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001746466
Websitehttps://equilliumbio.com
AI Summary
AI-generated1/26
minorneutraloperations update
Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference
Equillium announced new preclinical data from its EQ504 program will be presented in a poster at the 50th Anniversary La Jolla Immunology Conference, October 6-8, 2026.
The data show EQ504, an aryl hydrocarbon receptor (AhR) modulator, coordinating effects across epithelial and immune compartments in an intestinal co-culture model, preserving barrier integrity while suppressing inflammatory cytokines.
Management positions EQ504 as a potential oral, locally delivered therapy for ulcerative colitis; this is early-stage science with no clinical or financial milestones attached.